New Stock News | Oversubscribed nearly 700 times! Siasun Robot & Automation, a leading company in the medical field, officially closes its IPO on June 30 and lands on the Hong Kong Stock Exchange.

Domestic puncture mobile ablation surgery Siasun Robot & Automation leading enterprise Zhenjiankang Medical-B (02697) subscription has officially closed on June 25, with market funds showing strong interest in the segment track performance. According to Futu Securities' summary statistics, Zhenjiankang Medical's public offering this time corresponded to a fundraising size of approximately HK $48.27 million, with a total market financing subscription amount of up to HK $32.941 billion. The financing subscription multiple reached 682.43 times, showing significant fund enthusiasm. Nearly 20 securities firms participated in the financing subscription this time, with Futu Securities leading the way with a financing subscription amount of HK $22.951 billion; Tiger Brokers International and Huatai International followed closely behind, with financing subscription amounts of HK $4.107 billion and HK $1.713 billion respectively; Huali Securities and Zhifu Securities also saw their subscription amounts exceed HK $1 billion and HK $815 million respectively, showcasing the diverse channel funds seeing long-term growth potential in Zhenjiankang Medical. Zhenjiankang Medical's issuance price range is between HK $119.30 and HK $135.40 per share, with a trading unit of 20 shares per hand and an entry threshold of approximately HK $2,735.30 per hand. The first stock of puncture surgery Siasun Robot & Automation is expected to officially debut on the Hong Kong Stock Exchange mainboard on June 30, with CICC and DBS Asia Finance serving as the joint sponsors for this listing. With eight years of deep plowing in the puncture surgery Siasun Robot & Automation track, established in 2018, Zhenjiankang Medical, headquartered in the Greater Bay Area's depth cooperation zone, focuses on the entire chain self-research and commercialization of percutaneous puncture, ablation surgery Siasun Robot & Automation, and builds a complete tumor minimally invasive diagnosis and treatment product matrix. Its core product, percutaneous puncture surgery Siasun Robot & Automation, has developed four mature models: TH-S1, TH-S, TH-S Pro, and TH-SA, all of which have obtained NMPA Class III medical device registration certificates, covering the clinical needs of precise puncture in the lungs and abdominal organs. Third-party industry recognition consultation data confirms the leading position: by 2025, the company's market share in the percutaneous puncture surgery Siasun Robot & Automation track will be 36.4% in terms of shipments and 28.0% in revenue, maintaining the industry's leading position in both core dimensions. On the pipeline layout level, Zhenjiankang Medical is simultaneously building a ladder of products such as ablation surgery Siasun Robot & Automation, organ preservation, and other multiple tracks. The key product, ablation surgery Siasun Robot & Automation TH-X MW, has been recognized by the National Medical Products Administration as "internationally innovative" and has simultaneously obtained two major treatment indications for liver and lung tumors; the iterative model TH-X HMW has been approved for liver tumor ablation; meanwhile, there are reserved compact percutaneous puncture surgery Siasun Robot & Automation TH-P series, MW150 microwave equipment, cryoablation Siasun Robot & Automation TH-X Cryo, and internationally advanced and domestically scarce assessment equipment for external organ warm preservation, forming a dual-layer growth curve of short-term commercialization and medium and long-term frontier innovation. Market analysts point out that against the background of the industry's continuous expansion of demand for high-end medical equipment domestic substitution and tumor minimally invasive treatment, Zhenjiankang Medical holds dual core technology certifications of domestic and international innovation, coupled with the commercial track record of being the leader in the puncture track, highlighting its scarcity of hard technology attributes. The oversubscription of massive funds during the subscription stage fully reflects investors' high recognition of the track space and the company's growth certainty, with the grey market trend and debut performance potentially becoming the core sentiment indicator for the Hong Kong stock medical equipment and puncture surgery Siasun Robot & Automation segment.